Atopic Dermatitis
Tralokinumab treatment may neutralize IL-13 in patients with atopic dermatitis
Tralokinumab improved epidermal pathology, reduced inflammation and changed significant skin biomarkers in patients with atopic dermatitis, according to a study published in The European Journal of Allergy and Clinical Immunology.
Long-term dupilumab safe, efficacious in atopic dermatitis
Dupilumab showed continuous efficacy and safety in the long-term treatment of atopic dermatitis, according to a study.
Cendakimab effective, generally safe for moderate to severe atopic dermatitis
Cendakimab was effective and generally safe in the treatment of moderate to severe atopic dermatitis in adults, according to a press release.
Dermatologists play significant role in detecting, addressing body dysmorphic disorder
In a new study published in the Journal of Drugs in Dermatology, researchers discussed how and why dermatologists have a significant role to play in the diagnosing and addressing of body dysmorphic disorder.
Top news of July: Permanent makeup, FDA approvals, tattoos, more
Healio has compiled July’s most-read news in dermatology.
Imaging device tracks skin improvement following prebiotic treatment in skin of color
A new imaging device effectively monitored skin texture changes in patients with skin of color with atopic dermatitis and xerosis following a prebiotic skincare regimen, according to a study.
Recently published results highlight nemolizumab’s efficacy, safety in atopic dermatitis
New results evaluating the efficacy and safety of nemolizumab for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis were published in The Lancet, Galderma announced in a press release.
American Skin Association research grant recipients to target psoriasis, vitiligo, more
The American Skin Association has announced the recipients of its 2024 research grants for skin cancer and diseases, according to a press release.
Baricitinib, dupilumab see comparable real-world results in atopic dermatitis
Responses to baricitinib and dupilumab were notable and similar among patients with moderate to severe atopic dermatitis in a real-world setting, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
UK health authority recommends Ebglyss for atopic dermatitis treatment in England
The National Institute for Health and Care Excellence has recommended Ebglyss for the treatment of moderate to severe atopic dermatitis in the National Health Service England, according to an Almirall press release.